Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 8/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27577519 | 0.82 | MAOB (0.50) | MRGPRX4MAOBFFAR1NR4A2NR4A1 | |
| SCHEMBL2347876 | 0.81 | PTGS2 (0.45) | — | |
| SCHEMBL5042730 | 0.80 | HDAC8 (0.53) | MRGPRX4MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15472489 | 0.79 | ALOX5 (0.56) | MRGPRX4MAOBRAB9ASMN1; SMN2MAOA | |
| SCHEMBL9547737 | 0.79 | MAOB (0.50) | MRGPRX4MAOBFFAR1NR4A2PPARD | |
| SCHEMBL5042659 | 0.78 | MAOB (0.56) | MAOBFFAR1PPARGPPARANPC1 | |
| SCHEMBL28123955 | 0.78 | MAOB (0.49) | MRGPRX4MAOBFFAR1NR4A2PPARD | |
| SCHEMBL5038222 | 0.77 | KMT2A (0.60) | MRGPRX4MAOBSMN1; SMN2NR4A2 | |
| SCHEMBL30697636 | 0.77 | LMNA (0.54) | MRGPRX4MAOBFFAR1PPARGSMN1; SMN2 | |
| SCHEMBL27577521 | 0.76 | MAOB (0.47) | MRGPRX4MAOBNPC1RAB9AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | MRGPRX4 112/4885MAOB 553/4885FFAR1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.